Overview

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy ABV: Adriamycin (doxorubicin)/bleomycin/vincristine. To evaluate the safety and tolerance of DOX-SL compared to ABV in a population of AIDS patients with severe KS.

Phase:

Phase 3

Details

Lead Sponsor:

Sequus Pharmaceuticals

Treatments:

Bleomycin
Doxorubicin
Liposomal doxorubicin
Vincristine